Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022

SELL
$15.91 - $21.88 $338,564 - $465,606
-21,280 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$19.74 - $28.7 $127,855 - $185,889
6,477 Added 43.75%
21,280 $446,000
Q2 2021

Aug 13, 2021

BUY
$20.49 - $35.63 $303,313 - $527,430
14,803 New
14,803 $398,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Parkwood LLC Portfolio

Follow Parkwood LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkwood LLC with notifications on news.